LAVERDIA-CA1 (verdinexor): A new oral treatment option for canine lymphoma
1 hr CE Credit
Exclusively for Animal Dermatology Clinic
Watch On Demand
In this CE session, we'll review the latest best practices for managing canine lymphoma. We'll also talk about how the first FDA conditionally approved oral tablet to treat dogs with lymphoma, LAVERDIA™-CA1 (verdinexor), is giving veterinarians and clients more options and increasing access to cancer care.
LAVERDIA-CA1 (verdinexor) is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-526.
Dr. David Bruyette
DVM, DACVIM (SAIM)
Chief Medical Officer
- Evolving protocols for treating canine lymphoma
- How SINE class drugs, like LAVERDIA-CA1, work
- Clinical applications, including cutaneous lymphoma
- Guidelines to optimize patient outcomes